Exact Sciences Corporation $EXAS Shares Sold by Thompson Investment Management Inc.

Thompson Investment Management Inc. lessened its position in Exact Sciences Corporation (NASDAQ:EXAS) by 26.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 175,742 shares of the medical research company’s stock after selling 63,758 shares during the period. Exact Sciences comprises about 2.2% of Thompson Investment Management Inc.’s portfolio, making the stock its 5th largest holding. Thompson Investment Management Inc. owned 0.09% of Exact Sciences worth $17,848,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of EXAS. Westside Investment Management Inc. grew its holdings in Exact Sciences by 100.0% during the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after purchasing an additional 271 shares during the period. Quent Capital LLC acquired a new position in Exact Sciences during the third quarter worth approximately $48,000. True Wealth Design LLC raised its stake in Exact Sciences by 61.7% in the fourth quarter. True Wealth Design LLC now owns 983 shares of the medical research company’s stock valued at $100,000 after buying an additional 375 shares during the period. Bollard Group LLC bought a new stake in Exact Sciences in the third quarter valued at approximately $55,000. Finally, OFI Invest Asset Management lifted its position in shares of Exact Sciences by 241.2% in the third quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company’s stock valued at $59,000 after buying an additional 767 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS opened at $104.91 on Monday. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $104.98. The business has a 50 day moving average of $103.32 and a 200-day moving average of $87.90. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The stock has a market cap of $20.03 billion, a PE ratio of -95.37, a P/E/G ratio of 2.02 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). The firm had revenue of $878.38 million for the quarter, compared to the consensus estimate of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.Exact Sciences’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) EPS. As a group, equities research analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Analysts Set New Price Targets

EXAS has been the subject of several research analyst reports. Mizuho reiterated a “neutral” rating and set a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Evercore set a $105.00 price objective on shares of Exact Sciences and gave the stock an “in-line” rating in a research report on Monday, January 5th. Finally, BTIG Research reiterated a “neutral” rating on shares of Exact Sciences in a report on Tuesday, March 24th. Twenty-one equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $92.13.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.